ALLO 329 First Clinical Dataset in Autoimmune Disease

Company Allogene Therapeutics Event Type First-in-human Phase 1 data (RESOLUTION) Modality Allogeneic CAR T Asset ALLO-329 Target CD19; CD70 Disease Area Systemic sclerosis; myositis; lupus Summary Allogene disclosed first-in-human Phase 1 RESOLUTION data for its CD19/CD70 allogeneic CAR T therapy. Skin scores improved in eight…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *